The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
The Company's investment objective is the achievement of long term capital growth by investing primarily in listed companies throughout the world. While the policy is global investment, the approach adopted is to construct a portfolio through the identification of individual companies which offer long term growth potential, normally over at least a five year horizon and which at the point of initial investment have a market capitalisation no greater than the market capitalisation of the largest constituent of the Company’s comparative index(S&P Global Small Cap Index total return (in sterling terms)) measured by market capitalisation.
The annual management fee will be as follows 0.75% on the first GBP 50m of NAV, 0.65% on the next GBP 200m of NAV and 0.55% on the remaining NAV. The fees are calculated on a quarterly basis. The contract is terminable on 3 month notice.
Dividend Policy
The Board does not intend to draw on the revenue reserve of Company to pay or maintain dividends. The Company objective is that of generating capital growth and investors should not expect any income from this investment.
ASSET SPLIT
Total number of holdings: 99.
Trust Manager
Douglas Brodie
Manager Bio
Douglas Brodie joined Baillie Gifford in 2001 and is Head of the Discovery Team. Mr. Brodie became a Partner in 2015 and is a CFA Charterholder. He graduated BSc in Molecular Biology & Biochemistry from the University of Durham in 1997 and attained a DPhil in Molecular Immunology from the University of Oxford in 2001. Mr. Brodie has been a member of the team in 2021.
Board Of Directors
Jonathan Simpson-Dent, Gregory Eckersley, Mungo Wilson, Caroline Roxburgh, Jane McCracken, Mary Gunn
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
Our analysts have selected this fund for the Wealth Shortlist.
Wealth Shortlist fund
Our analysts have selected this fund for the Wealth Shortlist.
Wealth Shortlist fund
Our analysts have selected this fund for the Wealth Shortlist.
Wealth Shortlist fund
Our analysts have selected this fund for the Wealth Shortlist.
Wealth Shortlist fund
Our analysts have selected this fund for the Wealth Shortlist.
Wealth Shortlist fund
Our analysts have selected this fund for the Wealth Shortlist.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.
This website uses cookies
To help personalise your experience with HL and show you relevant content and adverts, we use cookies.
By clicking "Accept All Cookies", you consent to our use of cookies. You can change this at any time. If you want to know more, read our cookie policy.
Cookie settings
To make sure you get the most from our website, we use cookies.
Essential Cookies
These allow our website to work properly and gives us anonymous
information about how the website is used.
Functional cookies
The website will remember you (for example, for faster login) and help
us understand how you use the site.
Marketing cookies
You'll see tailored adverts. If you turn these off, you will still see
adverts but they may not be relevant to your interests.